{
    "nctId": "NCT03050398",
    "briefTitle": "A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib",
    "officialTitle": "A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Identify Mutations of Genes From Tissue Samples Between Baseline and Time to Progression to Determine Modes of Resistance to Ribociclib After Disease Progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent was to have been obtained prior to any baseline/screening procedures.\n* Patients eligible for this companion sample collection protocol sample collection protocol must have met all inclusion in CLEE011A2404.\n\nExclusion Criteria:\n\n* Patients eligible for this companion sample collection protocol must not have met any of the exclusion criteria in the CLEE011A2404 study, in addition to the following:\n* Patients without either fresh or archival tumor tissue accessible.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}